An open trial of climatotherapy at the dead sea for patch-stage mycosis fungoides - 24/08/11
Petah Tikva and Jerusalem, Israel; and New Brunswick, New Jersey
Abstract |
Background |
Climatotherapy at the Dead Sea (CDS) is a well-established therapeutic modality for moderate to severe psoriasis vulgaris, resulting in sustained remissions. It has also been found to be effective for atopic dermatitis, another T-cell–mediated dermatosis.
Objective |
We sought to prospectively evaluate the efficacy of CDS in patch-stage mycosis fungoides.
Methods |
A total of 12 patients with patch-stage mycosis fungoides (6 with stage IA and 6 with stage IB) were treated with CDS as monotherapy for 28 consecutive days according to the protocol for psoriasis, ie, a gradual increase of sun exposure to a maximum of 3 hours daily.
Results |
A total of 9 patients achieved a complete clinical response (CCR), defined as no disease activity present; 2 achieved an almost CCR, defined as the reduction by more than 90% of disease activity; and 1 achieved a partial response, ie, reduction by more than 50% of disease activity. A CCR was achieved in all the patients with stage IA disease and in 3 of the 6 patients with stage IB disease. Of the 9 with a CCR, 6 also showed histopathologic clearing. Duration of the remissions, during which no therapy was allowed except for emollients, lasted from 2 to 9 months (mean: 5 months). No serious short-term side effects were recorded.
Conclusion |
CDS appears to be an effective, well-tolerated therapy for patch-stage mycosis fungoides.
Le texte complet de cet article est disponible en PDF.Plan
Supported by the Dead Sea Medical Research Center, the Dead Sea, Israel. Conflicts of interest: None identified. Presented at the European Organization for Research and Therapy of Cancer Cutaneous Lymphoma Project Group Meeting, in Oxford, United Kingdom, in September 2001. |
Vol 51 - N° 1
P. 33-38 - juillet 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?